Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 11/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10233567 | 0.83 | HRH3 (0.50) | HRH3MCHR1SMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL10233558 | 0.80 | MAPT (0.39) | HRH3MCHR1MAPT | |
| SCHEMBL14006989 | 0.80 | NCF1 (0.41) | SMN1; SMN2HSD17B10NPC1ALDH1A1TP53 | |
| SCHEMBL972022 | 0.74 | HRH3 (0.43) | HRH3MCHR1 | |
| SCHEMBL2669043 | 0.73 | HTR7 (0.47) | HRH3HTR7 | |
| SCHEMBL5911169 | 0.68 | NCF1 (0.63) | HRH3MCHR1HTR2A | |
| SCHEMBL805088 | 0.68 | SMN1; SMN2 (0.42) | SMN1; SMN2HSD17B10NPC1ALDH1A1TP53 | |
| Hydrochloric Acid SCHEMBL29733282 | 0.66 | SMN1; SMN2 (0.41) | SMN1; SMN2HSD17B10NPC1ALDH1A1TP53 | |
| SCHEMBL13668639 | 0.66 | SMN1; SMN2 (0.38) | SMN1; SMN2HSD17B10NPC1ALDH1A1TP53 | |
| SCHEMBL3160366 | 0.65 | SMN1; SMN2 (0.40) | SMN1; SMN2HSD17B10NPC1ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173649-B2 | Glucokinase activator | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20100016304-A1 | GLUCOKINASE ACTIVATOR | TEIJIN LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016304-A1 | GLUCOKINASE ACTIVATOR | GCK, GCKR, GALK1 | HRH3 4019/4885MCHR1 3652/4885SMN1; SMN2 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.